|
CH683149A5
(fr)
*
|
1991-07-22 |
1994-01-31 |
Debio Rech Pharma Sa |
Procédé pour la préparation de microsphères en matériau polymère biodégradable.
|
|
FR2693905B1
(fr)
*
|
1992-07-27 |
1994-09-02 |
Rhone Merieux |
Procédé de préparation de microsphères pour la libération prolongée de l'hormone LHRH et ses analogues, microsphères et formulations obtenues.
|
|
US5981719A
(en)
|
1993-03-09 |
1999-11-09 |
Epic Therapeutics, Inc. |
Macromolecular microparticles and methods of production and use
|
|
US6090925A
(en)
|
1993-03-09 |
2000-07-18 |
Epic Therapeutics, Inc. |
Macromolecular microparticles and methods of production and use
|
|
US6191105B1
(en)
|
1993-05-10 |
2001-02-20 |
Protein Delivery, Inc. |
Hydrophilic and lipophilic balanced microemulsion formulations of free-form and/or conjugation-stabilized therapeutic agents such as insulin
|
|
JP2944419B2
(ja)
|
1993-05-10 |
1999-09-06 |
ノバルティス アクチエンゲゼルシャフト |
持続性遊離組成物中の薬理学的活性成分の安定
|
|
US5681811A
(en)
*
|
1993-05-10 |
1997-10-28 |
Protein Delivery, Inc. |
Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations comprising same, and method of making and using the same
|
|
DE4320201A1
(de)
*
|
1993-06-18 |
1995-01-12 |
Asta Medica Ag |
Verwendung von Cetrorelix und weiteren Nona- und Dekapeptiden zur Herstellung eines Arzneimittels zur Bekämpfung von Aids und zur Wachstumsstimulation
|
|
US6087324A
(en)
*
|
1993-06-24 |
2000-07-11 |
Takeda Chemical Industries, Ltd. |
Sustained-release preparation
|
|
DE4342092B4
(de)
*
|
1993-12-09 |
2007-01-11 |
Zentaris Gmbh |
Langwirkende Injektionssuspension und Verfahren zur Herstellung
|
|
WO1997001331A2
(en)
|
1995-06-27 |
1997-01-16 |
Takeda Chemical Industries, Ltd. |
Method of producing sustained-release preparation
|
|
DE19545257A1
(de)
|
1995-11-24 |
1997-06-19 |
Schering Ag |
Verfahren zur Herstellung von morphologisch einheitlichen Mikrokapseln sowie nach diesem Verfahren hergestellte Mikrokapseln
|
|
KR0162872B1
(ko)
*
|
1996-04-01 |
1998-12-01 |
김은영 |
용매추출법을 이용한 생분해성 고분자 미립구의 개선된 제조방법 및 이를 이용한 국소염증 질환 치료용 미립구의 제조방법
|
|
US20020111603A1
(en)
*
|
1996-12-02 |
2002-08-15 |
Societe De Conseils De Recherches Et D'application |
Device for local administration of solid or semi-solid formulations and delayed-release formulations for proposal parental administration and preparation process
|
|
AU5678398A
(en)
*
|
1997-01-29 |
1998-08-18 |
Takeda Chemical Industries Ltd. |
Sustained-release microspheres, their production and use
|
|
AR012448A1
(es)
*
|
1997-04-18 |
2000-10-18 |
Ipsen Pharma Biotech |
Composicion en forma de microcapsulas o de implantes que comprende un excipiente biodegradable, polimero o co-polimero, o una mezcla de talesexcipientes, y una sustancia activa o una mezcla de sustancias activas, procedimiento para la preparacion de una sustancia soluble en agua de elevada
|
|
US6465015B1
(en)
*
|
1998-02-24 |
2002-10-15 |
Arch Chemicals, Inc. |
Sonic method of enhancing chemical reactions to provide uniform, non-agglomerated particles
|
|
US6613358B2
(en)
|
1998-03-18 |
2003-09-02 |
Theodore W. Randolph |
Sustained-release composition including amorphous polymer
|
|
EP1073419A4
(en)
*
|
1998-03-18 |
2009-03-25 |
Univ Technology Corp |
COMPOSITION, CONTAINING AMORPHOUS POLYMER, FOR DELAYED RELEASE.
|
|
SE9801288D0
(sv)
*
|
1998-04-14 |
1998-04-14 |
Astra Ab |
Vaccine delivery system and metod of production
|
|
DK1098660T3
(da)
*
|
1998-07-23 |
2003-02-17 |
Sod Conseils Rech Applic |
Indkapsling af vandopløselige peptider
|
|
US6270700B1
(en)
|
1998-07-23 |
2001-08-07 |
Societe De Conseils De Recherches Et D'applications Scientifiques, Sas |
Encapsulation of water soluble peptides
|
|
EP1240896A3
(en)
*
|
1998-07-23 |
2003-03-26 |
Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. |
Encapsulation of water soluble peptides
|
|
WO2000004916A1
(en)
*
|
1998-07-23 |
2000-02-03 |
Societe De Conseils De Recherches Et D'applications Scientifiques Sas |
Encapsulation of water soluble peptides
|
|
US20070009605A1
(en)
*
|
1998-07-23 |
2007-01-11 |
Ignatious Francis X |
Encapsulation of water soluble peptides
|
|
US6703381B1
(en)
|
1998-08-14 |
2004-03-09 |
Nobex Corporation |
Methods for delivery therapeutic compounds across the blood-brain barrier
|
|
GB2344519B
(en)
*
|
1998-12-07 |
2004-05-19 |
Johnson & Johnson Medical Ltd |
Sterile therapeutic compositions
|
|
IT1304152B1
(it)
*
|
1998-12-10 |
2001-03-08 |
Mediolanum Farmaceutici Srl |
Composizioni comprendenti un peptide ed acido polilattico-glicolicoatte alla preparazione di impianti sottocutanei aventi un prolungato
|
|
US6682724B2
(en)
|
1999-02-23 |
2004-01-27 |
Arch Chemcials, Inc. |
Sonic method of enhancing chemical reactions to provide uniform, non-agglomerated particles
|
|
US6204308B1
(en)
|
1999-03-01 |
2001-03-20 |
Novartis Ag |
Organic compounds
|
|
US6317623B1
(en)
*
|
1999-03-12 |
2001-11-13 |
Medrad, Inc. |
Apparatus and method for controlling contrast enhanced imaging procedures
|
|
JP2002539172A
(ja)
|
1999-03-17 |
2002-11-19 |
ノバルティス アクチエンゲゼルシャフト |
Ｔｇｆ−ベータを含む医薬組成物
|
|
EP1044683A1
(en)
*
|
1999-04-15 |
2000-10-18 |
Debio Recherche Pharmaceutique S.A. |
One-step dispersion method for the microencapsulation of water soluble substances
|
|
US7169889B1
(en)
|
1999-06-19 |
2007-01-30 |
Biocon Limited |
Insulin prodrugs hydrolyzable in vivo to yield peglylated insulin
|
|
ES2169980B1
(es)
|
1999-12-17 |
2003-11-01 |
Lipotec Sa |
Microcapsulas para la liberacion prolongada de farmacos.
|
|
US6309454B1
(en)
|
2000-05-12 |
2001-10-30 |
Johnson & Johnson Medical Limited |
Freeze-dried composite materials and processes for the production thereof
|
|
US7252842B2
(en)
|
2000-12-21 |
2007-08-07 |
Alrise Biosystems Gmbh |
Induced phase transition method for the production of microparticles containing hydrophilic active agents
|
|
US7060675B2
(en)
|
2001-02-15 |
2006-06-13 |
Nobex Corporation |
Methods of treating diabetes mellitus
|
|
US6867183B2
(en)
|
2001-02-15 |
2005-03-15 |
Nobex Corporation |
Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
|
|
US6858580B2
(en)
|
2001-06-04 |
2005-02-22 |
Nobex Corporation |
Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
|
|
US6713452B2
(en)
|
2001-06-04 |
2004-03-30 |
Nobex Corporation |
Mixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
|
|
US6828297B2
(en)
|
2001-06-04 |
2004-12-07 |
Nobex Corporation |
Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
|
|
US7312192B2
(en)
|
2001-09-07 |
2007-12-25 |
Biocon Limited |
Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
|
|
US7196059B2
(en)
|
2001-09-07 |
2007-03-27 |
Biocon Limited |
Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
|
|
US7166571B2
(en)
|
2001-09-07 |
2007-01-23 |
Biocon Limited |
Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
|
|
US6913903B2
(en)
|
2001-09-07 |
2005-07-05 |
Nobex Corporation |
Methods of synthesizing insulin polypeptide-oligomer conjugates, and proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
|
|
AU2002337692B2
(en)
*
|
2001-09-26 |
2007-09-13 |
Baxter International Inc. |
Preparation of submicron sized nanoparticles via dispersion and solvent or liquid phase removal
|
|
US20060003012A9
(en)
*
|
2001-09-26 |
2006-01-05 |
Sean Brynjelsen |
Preparation of submicron solid particle suspensions by sonication of multiphase systems
|
|
US7112340B2
(en)
*
|
2001-10-19 |
2006-09-26 |
Baxter International Inc. |
Compositions of and method for preparing stable particles in a frozen aqueous matrix
|
|
KR100885070B1
(ko)
*
|
2002-05-08 |
2009-02-25 |
재단법인서울대학교산학협력재단 |
Ｐｌｇａ에 특이적으로 부착하는 올리고 펩타이드
|
|
AU2003236521A1
(en)
|
2002-06-13 |
2003-12-31 |
Nobex Corporation |
Methods of reducing hypoglycemic episodes in the treatment of diabetes mellitus
|
|
US7655618B2
(en)
*
|
2002-12-27 |
2010-02-02 |
Diobex, Inc. |
Compositions and methods for the prevention and control of insulin-induced hypoglycemia
|
|
NZ541365A
(en)
*
|
2002-12-27 |
2009-09-25 |
Diobex Inc |
Compositions and methods for the prevention and control of insulin-induced hypoglycemia
|
|
US7772188B2
(en)
|
2003-01-28 |
2010-08-10 |
Ironwood Pharmaceuticals, Inc. |
Methods and compositions for the treatment of gastrointestinal disorders
|
|
ATE477268T1
(de)
|
2003-01-28 |
2010-08-15 |
Ironwood Pharmaceuticals Inc |
Zusammensetzungen zur behandlung von magen-darm- störungen
|
|
CN1938040A
(zh)
*
|
2003-03-05 |
2007-03-28 |
Pr药品有限公司 |
缩宫素控释制剂及其应用方法
|
|
US6987111B2
(en)
*
|
2003-08-06 |
2006-01-17 |
Alkermes Controlled Therapeutics, Ii |
Aripiprazole, olanzapine and haloperidol pamoate salts
|
|
JP5105578B2
(ja)
|
2003-11-05 |
2012-12-26 |
サーコード バイオサイエンス インコーポレイテッド |
細胞接着のモジュレーター
|
|
CN103223160B
(zh)
*
|
2004-07-19 |
2015-02-18 |
比奥孔有限公司 |
胰岛素-低聚物共轭物,制剂及其用途
|
|
EP2594259A1
(en)
|
2004-08-04 |
2013-05-22 |
Brookwood Pharmaceuticals, Inc. |
Methods for manufacturing delivery devices and devices thereof
|
|
ES2255426B1
(es)
*
|
2004-10-19 |
2007-08-16 |
Gp Pharm, S.A. |
Formulacion farmaceutica que comprende microcapsulas de estatinas suspendidas en ester alquilicos de acidos grasos poliinsaturados (pufa).
|
|
EP1674082A1
(de)
|
2004-12-22 |
2006-06-28 |
Zentaris GmbH |
Verfahren zur Herstellung von sterilen Suspensionen oder Lyophilisaten schwerlöslicher basischer Peptidkomplexe, diese enthaltende pharmazeutische Formulierungen sowie ihre Verwendung als Arzneimittel
|
|
WO2006078903A1
(en)
*
|
2005-01-21 |
2006-07-27 |
Matthews Richard H |
Radiosensitizer formulations comprising nitrohistidine derivatives
|
|
JP2008539260A
(ja)
*
|
2005-04-25 |
2008-11-13 |
アムジエン・インコーポレーテツド |
ポロゲンを含む生分解性プチド徐放性組成物
|
|
US8168655B2
(en)
|
2005-05-17 |
2012-05-01 |
Sarcode Bioscience Inc. |
Compositions and methods for treatment of eye disorders
|
|
MX2007015183A
(es)
*
|
2005-06-14 |
2008-02-19 |
Baxter Int |
Formulaciones farmaceuticas para minimizar las interacciones farmaco-farmaco.
|
|
WO2007059515A2
(en)
*
|
2005-11-15 |
2007-05-24 |
Baxter International, Inc. |
Compositions of lipoxygenase inhibitors
|
|
RU2464972C2
(ru)
*
|
2005-12-22 |
2012-10-27 |
Новартис Аг |
Композиции с замедленным высвобождением, включающие октреотид и два или более сополимера полилактида и гликолида
|
|
US9301792B2
(en)
|
2006-01-27 |
2016-04-05 |
Stryker Corporation |
Low pressure delivery system and method for delivering a solid and liquid mixture into a target site for medical treatment
|
|
KR100722607B1
(ko)
|
2006-05-11 |
2007-05-28 |
주식회사 펩트론 |
분산성 및 주사 투여능이 향상된 서방성 미립구의 제조방법
|
|
US7403325B2
(en)
*
|
2006-05-19 |
2008-07-22 |
Xerox Corporation |
Electrophoretic display device
|
|
RU2326655C1
(ru)
*
|
2006-11-09 |
2008-06-20 |
Федеральное государственное учреждение "48 Центральный научно-исследовательский институт Министерства обороны Российской Федерации" |
Способ инкапсулирования белоксодержащих веществ в микросферы из сополимера полилактид-полигликолид
|
|
US8039461B1
(en)
|
2006-11-10 |
2011-10-18 |
Pisgah Laboratories, Inc. |
Physical states of a pharmaceutical drug substance
|
|
US20080293695A1
(en)
|
2007-05-22 |
2008-11-27 |
David William Bristol |
Salts of physiologically active and psychoactive alkaloids and amines simultaneously exhibiting bioavailability and abuse resistance
|
|
US7718649B1
(en)
|
2006-11-10 |
2010-05-18 |
Pisgah Labs, Inc. |
Physical states of a pharmaceutical drug substance
|
|
US8211905B1
(en)
|
2007-05-22 |
2012-07-03 |
Pisgah Laboratories, Inc. |
Opioid salts and formulations exhibiting anti-abuse and anti-dose dumping properties
|
|
US7858663B1
(en)
|
2007-10-31 |
2010-12-28 |
Pisgah Laboratories, Inc. |
Physical and chemical properties of thyroid hormone organic acid addition salts
|
|
US8329720B1
(en)
|
2007-05-22 |
2012-12-11 |
Pisgah Laboratories, Inc. |
Opioid salts and formulations exhibiting abuse deterrent and anti-dose dumping properties
|
|
US20080293814A1
(en)
*
|
2007-05-22 |
2008-11-27 |
Deepak Tiwari |
Concentrate esmolol
|
|
US9421266B2
(en)
|
2007-05-22 |
2016-08-23 |
Pisgah Laboratories, Inc. |
Safety of pseudoephedrine drug products
|
|
US8426467B2
(en)
*
|
2007-05-22 |
2013-04-23 |
Baxter International Inc. |
Colored esmolol concentrate
|
|
US10183001B1
(en)
|
2007-05-22 |
2019-01-22 |
Pisgah Laboratories, Inc. |
Opioid and attention deficit hyperactivity disorder medications possessing abuse deterrent and anti-dose dumping safety features
|
|
US8722736B2
(en)
*
|
2007-05-22 |
2014-05-13 |
Baxter International Inc. |
Multi-dose concentrate esmolol with benzyl alcohol
|
|
MX2009013293A
(es)
|
2007-06-04 |
2010-02-15 |
Synergy Pharmaceuticals Inc |
Agonistas de guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos.
|
|
US8969514B2
(en)
|
2007-06-04 |
2015-03-03 |
Synergy Pharmaceuticals, Inc. |
Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
|
|
HUE031550T2
(en)
*
|
2007-06-06 |
2017-07-28 |
Debiopharm Res & Mfg Sa |
Slow release pharmaceutical composition made of microparticles
|
|
US9241908B2
(en)
|
2007-10-16 |
2016-01-26 |
Biocon Limited |
Orally administrable solid pharmaceutical composition and a process thereof
|
|
MX2010004281A
(es)
|
2007-10-19 |
2010-09-10 |
Sarcode Corp |
Composiciones y metodos para el tratamiento de la retinopatia diabetica.
|
|
CA2709712C
(en)
|
2007-12-20 |
2016-05-10 |
Surmodics Pharmaceuticals, Inc. |
Process for preparing microparticles having a low residual solvent volume
|
|
US8883863B1
(en)
|
2008-04-03 |
2014-11-11 |
Pisgah Laboratories, Inc. |
Safety of psuedoephedrine drug products
|
|
WO2009139817A2
(en)
|
2008-04-15 |
2009-11-19 |
Sarcode Corporation |
Crystalline pharmaceutical and methods of preparation and use thereof
|
|
JP2011516607A
(ja)
*
|
2008-04-15 |
2011-05-26 |
サーコード コーポレイション |
胃腸系へのｌｆａ−１アンタゴニストの送達
|
|
EP2810951B1
(en)
|
2008-06-04 |
2017-03-15 |
Synergy Pharmaceuticals Inc. |
Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
|
|
CA2730603C
(en)
|
2008-07-16 |
2019-09-24 |
Synergy Pharmaceuticals Inc. |
Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
|
|
US20100062057A1
(en)
*
|
2008-09-10 |
2010-03-11 |
Pronova BioPharma Norge AS. |
Formulation
|
|
US9532963B2
(en)
|
2009-03-09 |
2017-01-03 |
Pronova Biopharma Norge As |
Compositions comprising a fatty acid oil mixture and a free fatty acid, and methods and uses thereof
|
|
US8378105B2
(en)
*
|
2009-10-21 |
2013-02-19 |
Sarcode Bioscience Inc. |
Crystalline pharmaceutical and methods of preparation and use thereof
|
|
ES2364011B1
(es)
|
2009-11-20 |
2013-01-24 |
Gp Pharm, S.A. |
Cápsulas de principios activos farmacéuticos y ésteres de ácidos grasos poliinsaturados para el tratamiento de enfermedades cardiovasculares.
|
|
ES2363964B1
(es)
|
2009-11-20 |
2012-08-22 |
Gp Pharm, S.A. |
Cápsulas de principios activos farmacéuticos y ésteres de ácidos grasos poliinsaturados.
|
|
ES2363965B1
(es)
|
2009-11-20 |
2013-01-24 |
Gp Pharm S.A. |
Cápsulas de principios activos betabloqueantes y ésteres de ácidos grasos poliinsaturados.
|
|
SG181446A1
(en)
|
2009-12-23 |
2012-07-30 |
Defiante Farmaceutica Sa |
Combination composition useful for treating cardiovascular diseases
|
|
ES2385240B1
(es)
|
2010-07-26 |
2013-09-23 |
Gp-Pharm, S.A. |
Cápsulas de principios activos farmacéuticos y ácidos grasos poliinsaturados para el tratamiento de enfermedades de la próstata.
|
|
US9616097B2
(en)
|
2010-09-15 |
2017-04-11 |
Synergy Pharmaceuticals, Inc. |
Formulations of guanylate cyclase C agonists and methods of use
|
|
ES2579319T3
(es)
|
2011-05-04 |
2016-08-09 |
Balance Therapeutics, Inc. |
Derivados de pentilenotetrazol
|
|
WO2013072767A1
(en)
|
2011-11-18 |
2013-05-23 |
Pronova Biopharma Norge As |
Compositions and preconcentrates comprising at least one salicylate and omega-3 fatty acid oil mixture
|
|
EP2833740B1
(en)
|
2012-04-04 |
2016-09-14 |
Pronova BioPharma Norge AS |
Compositions comprising omega-3 fatty acids and vitamin d for acne vulgaris and/or eczema, and methods and uses thereof
|
|
US9585896B2
(en)
|
2012-04-04 |
2017-03-07 |
Pronova Biopharma Norge As |
Compositions comprising omega-3 fatty acids and vitamin D for psoriasis, and methods and uses thereof
|
|
CN104284673B
(zh)
*
|
2012-05-14 |
2018-02-13 |
帝人株式会社 |
灭菌组合物
|
|
SI3715345T1
(sl)
|
2012-07-25 |
2024-07-31 |
Bausch + Lomb Ireland Limited |
Priprava zaviralca lfa-1
|
|
EP3718557A3
(en)
|
2013-02-25 |
2020-10-21 |
Bausch Health Ireland Limited |
Guanylate cyclase receptor agonist sp-333 for use in colonic cleansing
|
|
AU2014222389B2
(en)
|
2013-02-28 |
2018-11-29 |
Pronova Biopharma Norge As |
A composition comprising a lipid compound, a triglyceride, and a surfactant, and methods of using the same
|
|
JP2016514670A
(ja)
|
2013-03-15 |
2016-05-23 |
シナジー ファーマシューティカルズ インコーポレイテッド |
他の薬物と組み合わせたグアニル酸シクラーゼ受容体アゴニスト
|
|
JP2016514671A
(ja)
|
2013-03-15 |
2016-05-23 |
シナジー ファーマシューティカルズ インコーポレイテッド |
グアニル酸シクラーゼのアゴニストおよびその使用
|
|
WO2015054649A2
(en)
|
2013-10-10 |
2015-04-16 |
Synergy Pharmaceuticals, Inc. |
Agonists of guanylate cyclase useful for the treatment of opioid induced dysfunctions
|
|
US20160151511A1
(en)
|
2014-12-02 |
2016-06-02 |
Antriabio, Inc. |
Proteins and protein conjugates with increased hydrophobicity
|
|
US20180104201A1
(en)
|
2015-04-28 |
2018-04-19 |
Pronova Biopharma Norge As |
Use of structurally enhanced fatty acids containing sulphur for preventing and or treating non alcoholic steatohepatitis
|
|
JP2019506383A
(ja)
|
2016-01-11 |
2019-03-07 |
シナジー ファーマシューティカルズ インコーポレイテッド |
潰瘍性大腸炎を治療するための製剤および方法
|
|
EP3687503A1
(en)
|
2017-09-26 |
2020-08-05 |
Nanomi B.V. |
Method for preparing micro-particles by double emulsion technique
|
|
PT3720431T
(pt)
|
2017-12-06 |
2024-12-05 |
Basf As |
Derivados de ácidos gordos para o tratamento da esteato-hepatite não alcoólica
|
|
WO2026050206A1
(en)
|
2024-08-27 |
2026-03-05 |
Ironwood Pharmaceuticals, Inc. |
Combinations of glp-1 and guanylate cyclase c (gc-c) receptor agonists
|